These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 19655166)

  • 1. Glycolytic phenotype in breast cancer: activation of Akt, up-regulation of GLUT1, TKTL1 and down-regulation of M2PK.
    Schmidt M; Voelker HU; Kapp M; Krockenberger M; Dietl J; Kammerer U
    J Cancer Res Clin Oncol; 2010 Feb; 136(2):219-25. PubMed ID: 19655166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinicopathological and prognostic relevance of pyruvate kinase M2 and pAkt expression in breast cancer.
    Benesch C; Schneider C; Voelker HU; Kapp M; Caffier H; Krockenberger M; Dietl J; Kammerer U; Schmidt M
    Anticancer Res; 2010 May; 30(5):1689-94. PubMed ID: 20592362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of transketolase-like 1 protein (TKTL1) in human endometrial cancer.
    Krockenberger M; Engel JB; Schmidt M; Kohrenhagen N; Häusler SF; Dombrowski Y; Kapp M; Dietl J; Honig A
    Anticancer Res; 2010 May; 30(5):1653-9. PubMed ID: 20592357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of DJ-1 as a secretory molecule: retrospective study of DJ-1 expression at mRNA and protein levels in ductal carcinoma of the breast.
    Tsuchiya B; Iwaya K; Kohno N; Kawate T; Akahoshi T; Matsubara O; Mukai K
    Histopathology; 2012 Jul; 61(1):69-77. PubMed ID: 22385318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The level of phosphorylated Akt predominantly reflects the expressive status of CerbB2 in invasive breast cancer.
    Chi Y; Zhao J; Cui SP; Jiang P; Wang HL; Zhang H; Mao JZ; Liu HJ; Hou L; Zhang B
    Histol Histopathol; 2013 May; 28(5):655-61. PubMed ID: 23420345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microcysts and breast cancer: a study of biological markers in archival biopsy material.
    Tran DD; Lawson JS
    Breast Cancer Res Treat; 2002 Oct; 75(3):213-20. PubMed ID: 12353810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Over-Expressed Twist Associates with Markers of Epithelial Mesenchymal Transition and Predicts Poor Prognosis in Breast Cancers via ERK and Akt Activation.
    Zhang YQ; Wei XL; Liang YK; Chen WL; Zhang F; Bai JW; Qiu SQ; Du CW; Huang WH; Zhang GJ
    PLoS One; 2015; 10(8):e0135851. PubMed ID: 26295469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
    Park SS; Kim SW
    Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promoter hypermethylation in ductal carcinoma in situ of the male breast.
    Vermeulen MA; van Deurzen CHM; Doebar SC; de Leng WWJ; Martens JWM; van Diest PJ; Moelans CB
    Endocr Relat Cancer; 2019 Jun; 26(6):575-584. PubMed ID: 30921768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast.
    Lebeau A; Unholzer A; Amann G; Kronawitter M; Bauerfeind I; Sendelhofert A; Iff A; Löhrs U
    Breast Cancer Res Treat; 2003 May; 79(2):187-98. PubMed ID: 12825853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis.
    Bos R; Zhong H; Hanrahan CF; Mommers EC; Semenza GL; Pinedo HM; Abeloff MD; Simons JW; van Diest PJ; van der Wall E
    J Natl Cancer Inst; 2001 Feb; 93(4):309-14. PubMed ID: 11181778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR; Abd-Elwahed SR; Abdulwahed AR
    Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucose metabolism and angiogenesis in granulosa cell tumors of the ovary: activation of Akt, expression of M2PK, TKTL1 and VEGF.
    Schmidt M; Kammerer U; Segerer S; Cramer A; Kohrenhagen N; Dietl J; Voelker HU
    Eur J Obstet Gynecol Reprod Biol; 2008 Jul; 139(1):72-8. PubMed ID: 18394773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics.
    Ringberg A; Anagnostaki L; Anderson H; Idvall I; Fernö M;
    Eur J Cancer; 2001 Aug; 37(12):1514-22. PubMed ID: 11506959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association between Akt activation and resistance to hormone therapy in metastatic breast cancer.
    Tokunaga E; Kataoka A; Kimura Y; Oki E; Mashino K; Nishida K; Koga T; Morita M; Kakeji Y; Baba H; Ohno S; Maehara Y
    Eur J Cancer; 2006 Mar; 42(5):629-35. PubMed ID: 16464571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrix metalloproteinase-9 as a potential tumor marker in breast cancer.
    Nanda DP; Sil H; Moulik S; Biswas J; Mandal SS; Chatterjee A
    J Environ Pathol Toxicol Oncol; 2013; 32(2):115-29. PubMed ID: 24099425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.
    Frogne T; Laenkholm AV; Lyng MB; Henriksen KL; Lykkesfeldt AE
    Breast Cancer Res; 2009; 11(1):R11. PubMed ID: 19239686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence.
    Han K; Nofech-Mozes S; Narod S; Hanna W; Vesprini D; Saskin R; Taylor C; Kong I; Paszat L; Rakovitch E
    Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):183-9. PubMed ID: 21958729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential Gene Expression in Ductal Carcinoma In Situ of the Breast Based on ERBB2 Status.
    Agosto-Arroyo E; Isayeva T; Wei S; Almeida JS; Harada S
    Cancer Control; 2017 Jan; 24(1):102-110. PubMed ID: 28178722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.